CV
For a detailed overview of my research experience, publications, and skills, please download my CV in PDF format.
Basics
| Name | Arash Nabbi |
| Label | Senior Scientist, Oncology R&D |
| arash.nabbi@astrazeneca.com | |
| Phone | 647-980-7411 |
| Url | https://anabbi.github.io |
| Summary | Computational biologist and pharmacist focusing on biomarker research for immuno-oncology. |
Work
-
2024.07 - Present Senior Scientist, Oncology Data Science
AstraZeneca Canada
Oncology R&D, biomarker research for immuno-oncology
-
2022.08 - 2024.07 Scientific Associate I
University Health Network, Princess Margaret Cancer Centre
Translational research in pediatric cancer immunogenomics
Education
-
2010.09 - 2017.01 Calgary, AB, Canada
-
2004.01 - 2009.12 Tehran, Iran
Publications
-
2023.09.07 Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours
Genome Medicine
Nabbi A*, Beck P*, et al. Genome Med. 2023 Sep 7;15(1):67.
-
2023.04.01 Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab
Nature Cancer
Nabbi A, et al. Nat Cancer. 2023 Apr;4(4):502-515.
-
2022.01.01 Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency
Nature Medicine
Das A, et al. (including Nabbi A). Nat Med. 2022 Jan;28(1):125-135.
-
2017.05.16 ING3 promotes prostate cancer growth by activating the androgen receptor
BMC Medicine
Nabbi A, et al. BMC Med. 2017 May 16;15(1):103.
Skills
| Computational Biology | |
| Bioinformatics | |
| Genomics | |
| Transcriptomics | |
| Single-cell RNA-seq | |
| Immunogenomics |
| Cancer Biology | |
| Tumor microenvironment | |
| Cancer immunotherapy | |
| Biomarker discovery |
Languages
| English | |
| Fluent |
| Farsi | |
| Native |
| German | |
| Intermediate |
Interests
| Immuno-Oncology | |
| Predictive immune biomarkers | |
| Cancer immunotherapy targets | |
| Tumour-Immune evolution |